USPTO serial 87379725
EPIMMUNE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- NELMAN, JESSE M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EPIMMUNE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.1100 NEW YORK AVENUE, N.W.WASHINGTON, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Peptides for industrial purpose for analyzing and detecting certain cytokines, biomarkers, and toxins for laboratory or research use; reagents for scientific or medical research use; protein in raw material form for scientific or laboratory purposes; protein raw material form for scientific and medical research; chemical additives for use in the manufacture of food, food preservative compositions, chemical substances for preserving foodstuffs, namely, food preservatives; artificial sweeteners for beverages; biological preparations other than for medical or veterinary purposes for use in cell cultures; stem cells other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Food for babies except lacteal flour for babies; lacteal flour for babies; pharmaceutical preparations for prevention and treatment of cancer; vaccines; pharmaceutical and veterinary preparations for treatment of central or peripheral nervous system related diseases; pharmaceutical and veterinary preparations for treatment of cancer or tumor disease; pharmaceutical and veterinary preparations for treatment of benign prostatic hyperplasia; preparations for use in making medicated beverages, namely, powdered nutritional and dietary supplement drink mixes, dietary supplements for human consumption; protein dietary supplements; diet capsules; dietary supplements for animals; dietary supplements; nutraceuticals for use as dietary supplements; drug delivery agents in the form of capsules, powders, tablets, or edible wafers that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for diagnosis of benign prostatic hyperplasia; vitamin based beverages for medical purposes; functional beverages for relieving and preventing hangovers, namely, electrolyte drinks for medical purposes; amino acid containing beverages, namely, beverages for use as a nutritional supplement; plant extract other than for medical or veterinary purposes for use in the manufacture of dietary supplements; amino acid for use in the manufacture of dietary supplements | ACTIVE | — |
| 035 | Providing consumer information services in the field of peptide medical products; providing a web site featuring consumer information about peptides in the fields of health and nutrition; providing consumer information about dietary supplements and nutrition in relation to peptides; consumer survey services in the field of cosmetics | ACTIVE | — |
| 042 | Research and development of vaccines and medicines; Medical research in the field of cancer; Pharmaceutical development; Pharmaceutical research services; Cosmetology research; Cosmetic research; Research and development of DNA chips; Biotechnology research; Advisory services relating to biotechnology; Biological research; Gene analysis for scientific research purposes; Scientific research in the field of genetics; Chemical analysis; Chemistry services, namely, chemistry consultation, research in the field of chemistry, laboratory analysis in the field of chemistry; Research and analysis in the field of chemistry; Chemical research; Computer software development; Computer software research; Design of computer microchips | ACTIVE | — |
| 044 | Providing medical and healthcare information in the field of peptide medical products; medical skin care services; medical clinic services, namely, microdermabrasion, laser peels, skin care, and facials for prevention or treatment of general or localized inflammatory disease; providing information about dietary supplements and nutrition in relation to peptides; dietary and nutritional guidance; providing information about dietary food supplements for medical purposes in field of anti-inflammatory and anticancer; providing information about medical supplements for treatment of bone, joint, muscle and connective tissue related diseases; dispensing of Korean pharmaceuticals; dental services, namely, dental consultations, dentist services, dental hygienist services, and dental imaging services; health care; hair health care services; cosmetic surgery; medical assistance; scalp care services; beauty salons; make-up application services; beauty consultancy services; obesity consultation services; dental assistant services in the nature of medical assistance, namely, oral medical care services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Epimmune Inc.
- Other trademarks owned by Epimmune Inc.
- Other trademarks owned by Sangjae KIM
- Other trademarks owned by Sangjae KIM
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EPIMMUNE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 7, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 7, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 8, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 7, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 7, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 23, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 23, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 2, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 31, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 31, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 31, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 11, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 9, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 9, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 9, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 25, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 23, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 23, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 23, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 23, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 1, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 6, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 6, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 14, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 28, 2018 | ALIE | ASSIGNED TO LIE | — |
| Jan 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 18, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 18, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 18, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 18, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 10, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 10, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 10, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 19, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 19, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 19, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 20, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 20, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 20, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 24, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 24, 2017 | NWAP | NEW APPLICATION ENTERED | — |